rosiglitazone has been researched along with Arteriosclerosis in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 16 (88.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, H; Dvir, A; Gerber, Y; Harats, D; Levi, Z; Levkovitz, H; Ravid, M; Rhachmani, R; Shaish, A; Trestman, S; Yacov, N | 1 |
| Viberti, GC | 1 |
| Badiwala, MV; Fedak, PW; Li, RK; Li, SH; Mickle, DA; Verma, S; Wang, CH; Weisel, RD | 1 |
| Evans, M; Rees, A; Roberts, AW; Thomas, A | 1 |
| Kumar, AP; Piedrafita, FJ; Reynolds, WF | 1 |
| Ishii, T; Itoh, K; Leake, DS; Mann, GE; Ruiz, E; Unoki, H; Yamamoto, M | 1 |
| Baker, DL; Balazs, L; Bittman, R; Byun, HS; Johnson, LR; Makarova, N; Marathe, GK; McIntyre, TM; Prestwich, GD; Tigyi, G; Xu, Y; Yasuda, S; Zhang, C | 1 |
| Füchtenbusch, M; Löbner, K | 1 |
| Hitoglou-Makedou, AD; Kazakos, KA; Lasaridis, AN; Mouslech, TF; Nilsson, PM; Sarafidis, PA; Stafylas, PC; Tourkantonis, AA; Yovos, JG | 1 |
| Boer, MW; de Boer, JF; Hillebrands, JL; Klatter, FA; Navis, G; Onuta, G; Rienstra, H; Roks, AJ; Rozing, J; Uges, DR | 1 |
| Alvarez, JG; Evans, RM; Nagy, L; Thomazy, VA; Tontonoz, P | 1 |
| Antonucci, M; Chapman, J; Chinetti, G; Delerive, P; Fruchart, JC; Griglio, S; Majd, Z; Najib, J; Staels, B; Torra, IP | 1 |
| Brown, KK; Glass, CK; Li, AC; Palinski, W; Silvestre, MJ; Willson, TM | 1 |
| Boullier, A; Chang, MK; Glass, CK; Green, SR; Han, KH; Li, A; Quehenberger, O | 1 |
| Collins, AR; Hsueh, WA; Jackson, S; Kintscher, U; Law, RE; Meehan, WP; Noh, G; Palinski, W; Wakino, S | 1 |
| Eriksson, U; Hansson, GK; Romert, A; Sirsjö, A; Törmä, H; Wuttge, DM | 1 |
| Hsueh, WA; Law, RE | 1 |
| Grüb, M; Hombach, V; Kehrle, B; Koenig, W; Kohlhammer, K; Libby, P; Marx, N; Plutzky, J | 1 |
4 review(s) available for rosiglitazone and Arteriosclerosis
| Article | Year |
|---|---|
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Restenosis; Diabetes Mellitus, Type 2; Endothelin-1; Endothelium, Vascular; Humans; Hyperglycemia; Insulin Resistance; Lipoproteins; Matrix Metalloproteinases; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2003 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Glucose; Body Weight; C-Reactive Protein; Chronic Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Exercise; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metabolic Syndrome; Obesity; Research; Risk Factors; Rosiglitazone; Thiazolidinediones | 2004 |
PPARgamma and atherosclerosis: effects on cell growth and movement.
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Endothelium, Vascular; Humans; Metabolic Syndrome; Muscle, Smooth, Vascular; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
1 trial(s) available for rosiglitazone and Arteriosclerosis
| Article | Year |
|---|---|
The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
Topics: Aged; Arteriosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Fibrinogen; Homocysteine; Humans; Hypertension; Hypoglycemic Agents; Lipoprotein(a); Male; Middle Aged; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones | 2005 |
13 other study(ies) available for rosiglitazone and Arteriosclerosis
| Article | Year |
|---|---|
Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Fibrinolytic Agents; Male; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone.
Topics: Arteriosclerosis; C-Reactive Protein; Endothelium, Vascular; Humans; Hyperglycemia; Hypoglycemic Agents; Rosiglitazone; Saphenous Vein; Thiazolidinediones | 2003 |
Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism.
Topics: Alu Elements; Animals; Arteriosclerosis; Binding Sites; Bone Marrow Cells; Cells, Cultured; Estradiol; Estrogen Receptor alpha; Estrogens; Gene Expression Regulation, Enzymologic; Genotype; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Macrophage Colony-Stimulating Factor; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Peroxidase; Polymorphism, Genetic; Promoter Regions, Genetic; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Receptors, LDL; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2004 |
Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal.
Topics: Adaptor Proteins, Signal Transducing; Aldehydes; Animals; Aorta; Arteriosclerosis; CD36 Antigens; DNA-Binding Proteins; Female; Gene Expression Regulation; Heat-Shock Proteins; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Homeodomain Proteins; Lipid Peroxidation; Lipoproteins, LDL; Macrophages, Peritoneal; Maleates; Membrane Proteins; Mice; Mice, Inbred ICR; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-E2-Related Factor 2; Oxidative Stress; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, Scavenger; Rosiglitazone; Sequestosome-1 Protein; Thiazolidinediones; Trans-Activators; Transcription Factors; Transcription, Genetic; Up-Regulation | 2004 |
Lysophosphatidic acid induces neointima formation through PPARgamma activation.
Topics: Analysis of Variance; Anilides; Animals; Arteriosclerosis; Calmodulin-Binding Proteins; Carotid Artery Diseases; CD36 Antigens; Cells, Cultured; Disease Models, Animal; DNA Primers; Growth Substances; Ligands; Lipoproteins, LDL; Lysophospholipids; Male; Muscle, Smooth; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Time Factors; Transcription Factors | 2004 |
Rosiglitazone attenuates transplant arteriosclerosis after allogeneic aorta transplantation in rats.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Cell Proliferation; Chemokine CXCL12; Chemokines, CXC; Forkhead Transcription Factors; Male; Muscle, Smooth, Vascular; PPAR gamma; Rats; Rats, Inbred BN; Rats, Inbred Lew; Rats, Inbred WF; Receptor, Platelet-Derived Growth Factor beta; Rosiglitazone; T-Lymphocytes, Regulatory; Thiazolidinediones; Transplantation Immunology; Transplantation, Homologous | 2007 |
PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.
Topics: Alitretinoin; Animals; Arteriosclerosis; CD36 Antigens; Cell Differentiation; Dimerization; Foam Cells; HL-60 Cells; Humans; Ligands; Lipoproteins, LDL; Macrophages; Membrane Proteins; Mice; Mice, Transgenic; Monocytes; Promoter Regions, Genetic; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, Lipoprotein; Receptors, Retinoic Acid; Receptors, Scavenger; Retinoid X Receptors; Rosiglitazone; Scavenger Receptors, Class B; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages.
Topics: Apoptosis; Arteriosclerosis; Caspase 3; Caspases; Cell Differentiation; Humans; Immunohistochemistry; Inflammation; Interferon-gamma; Ligands; Macrophages; NF-kappa B; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha | 1998 |
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
Topics: Animals; Arteriosclerosis; Base Sequence; CD36 Antigens; DNA Primers; Female; Gene Expression; Humans; Insulin Resistance; Ligands; Male; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxazoles; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, LDL; Receptors, Lipoprotein; Receptors, Scavenger; RNA, Messenger; Rosiglitazone; Scavenger Receptors, Class B; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Tyrosine | 2000 |
Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma.
Topics: Animals; Apolipoproteins B; Arteriosclerosis; Cells, Cultured; Down-Regulation; Humans; Linoleic Acid; Linoleic Acids; Linoleic Acids, Conjugated; Lipoproteins, LDL; Mice; Monocytes; Muscle, Smooth, Vascular; Phospholipids; Receptors, CCR2; Receptors, Chemokine; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Arteriosclerosis; Blood Glucose; Body Weight; Cell Movement; Cells, Cultured; Chemokine CCL2; Chromans; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Endothelium, Vascular; Flavonoids; Fructose; Humans; Insulin; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Receptors, LDL; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Vasodilator Agents | 2001 |
Induction of CD36 by all-trans retinoic acid: retinoic acid receptor signaling in the pathogenesis of atherosclerosis.
Topics: Arteriosclerosis; CD36 Antigens; Cell Line; Cells, Cultured; Fibrinolytic Agents; Gene Expression Regulation; Humans; Lipoproteins, LDL; Monocytes; Muscle, Smooth, Vascular; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 2001 |
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; CD4-Positive T-Lymphocytes; Cells, Cultured; Fenofibrate; Graft Survival; Heart Transplantation; Humans; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Peroxisome Proliferators; Pioglitazone; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |